Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Overview | 7 | 1 |
| Therapeutics Development | 8 | 4 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Products under Development by Stage of Development | 8 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Products under Development by Therapy Area | 9 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Products under Development by Indication | 10 | 2 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Products under Development by Companies | 14 | 3 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Therapeutics Assessment | 17 | 6 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 2 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Companies Involved in Therapeutics Development | 23 | 7 |
| Arrien Pharmaceuticals, LLC | 23 | 1 |
| Confluence Life Sciences, Inc. | 24 | 1 |
| Corvus Pharmaceuticals, Inc. | 25 | 1 |
| Genentech, Inc. | 26 | 1 |
| Japan Tobacco Inc. | 27 | 1 |
| Novartis AG | 28 | 1 |
| Principia Biopharma Inc. | 29 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Drug Profiles | 30 | 15 |
| ARN-4079 Drug Profile | 30 | 1 |
| JTE-051 Drug Profile | 31 | 1 |
| pazopanib hydrochloride Drug Profile | 32 | 7 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 39 | 1 |
| PRN-694 Drug Profile | 40 | 1 |
| Small Molecule to Inhibit ITK and TXK for Immunology and Oncology Drug Profile | 41 | 1 |
| Small Molecule to Inhibit ITK for Asthma Drug Profile | 42 | 1 |
| Small Molecule to Inhibit ITK for Autoimmune Disorders, Chronic Inflammation and Oncology Drug Profile | 43 | 1 |
| Small Molecules to Inhibit ITK for Oncology Drug Profile | 44 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Dormant Projects | 45 | 1 |
| Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) Featured News &Press Releases | 46 | 11 |
| Jul 21, 2016: Mateon Announces Enrollment of First Patient in Phase 2 Portion of PAZOFOS Study in Recurrent Ovarian Cancer | 46 | 1 |
| Mar 16, 2015: Cancer drug may reduce bleeding in patients with rare genetic disorder, HHT | 46 | 1 |
| Apr 01, 2014: Results from phase III patient preference study of GSK s Votrient (pazopanib) vs. Sutent (sunitinib) in advanced renal cell carcinoma published in Journal of Clinical Oncology | 47 | 1 |
| Mar 31, 2014: Votrient as maintenance therapy for advanced ovarian cancer in the EU | 48 | 1 |
| Aug 21, 2013: Pazopanib shows better quality-of-life in advanced kidney cancer | 49 | 1 |
| Aug 07, 2013: GSK seeks additional indication approval for Votrient from EMA | 50 | 1 |
| Jul 11, 2013: GlaxoSmithKline's cancer drug Votrient receives full EU approval | 50 | 1 |
| Jun 01, 2013: GSK's Votrient Meets Primary Endpoint In Phase III Clinical Trial As Maintenance Therapy In Women With Advanced Epithelial Ovarian Cancer | 51 | 1 |
| Jan 08, 2013: Combination Of Pazopanib And Paclitaxel May Slow Anaplastic Thyroid Cancer, Mayo Clinic Study Shows | 52 | 1 |
| Oct 01, 2012: GlaxoSmithKline's Votrient Meets Primary Endpoint In Pivotal Phase III Study Of Advanced Renal Cell Carcinoma | 53 | 1 |
| Aug 07, 2012: GlaxoSmithKline Receives Marketing Authorization From European Commission For Pazopanib | 54 | 1 |
| May 25, 2012: GSK Receives Positive Opinion From European CHMP For Pazopanib In Treatment Of Patients With Certain Advanced Soft Tissue Sarcomas | 55 | 1 |
| Apr 26, 2012: GSK's Votrient Receives FDA Approval For Treatment Of Advanced Soft Tissue Sarcoma | 55 | 1 |
| Mar 20, 2012: GSK Announces Positive Vote From FDA Panel For Pazopanib In Certain Advanced Soft Tissue Sarcomas | 55 | 1 |
| Mar 02, 2012: PHARMAC To Fund GSK's Kidney Cancer Drug, Votrient | 56 | 1 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |